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for the convenience of better readability and clarity, abbreviations for transport-
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were identical for human and rodents.absorption of lipophilic nutrients, solubilization and excretion of
cholesterol, as well as antimicrobial and metabolic effects. Tight
regulation of BA transporters via nuclear receptors is necessary
to maintain proper BA homeostasis. Hereditary and acquired
defects of BA transporters are involved in the pathogenesis of sev-
eral hepatobiliary disorders including cholestasis, gallstones, fatty
liver disease and liver cancer, but also play a role in intestinal and
metabolic disorders beyond the liver. Thus, pharmacological mod-
iﬁcation of BA transporters and their regulatory nuclear receptors
opens novel treatment strategies for a wide range of disorders.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
To exert their unique physiologic functions bile acids (BAs)
undergo enterohepatic circulation requiring active transport pro-
cesses through the liver and digestive tract [1] (Fig. 1). During
this tightly regulated cycle, a minor fraction (less than 3–5%) of
secreted BAs escapes intestinal reabsorption via feces and needs
to be replaced by de novo synthesis [1]. Maintenance of the enter-
ohepatic BA circulation is vital for several liver and gastrointesti-
nal functions including bile ﬂow, solubilization and excretion of
cholesterol, clearance of toxic molecules, intestinal absorption
of lipophilic nutrients, as well as metabolic and antimicrobial
effects [2]. Moreover, the enterohepatic circulation efﬁciently
preserves these precious molecules, since BA synthesis from cho-
lesterol involves 17 energy-consuming enzymatic steps [3]. In the
body, BAs are mainly present in their conjugated form, which
prevents unrestricted diffusion; therefore, BAs must be trans-
ported via energy-driven transport systems across the mem-
branes of cells involved in the enterohepatic circulation [4]. BA
transporters have different transport afﬁnities for various BA spe-
cies, but also for other endogenous and exogenous compounds
such as drugs and toxins (Table 1). The expression of genes
involved in BA homeostasis is tightly controlled by nuclear recep-
tors (NRs) which sense the intracellular concentrations of BAs; in
addition, post-transcriptional mechanisms such as insertion/
retrieval of transporters into/from the cell membrane regulate
the transport capacity via protein kinase C and mitogen-activated
protein kinase activation by BAs [5–8]. Together with transcrip-
tional regulation, such post-transcriptional changes ﬁne-tune13 vol. 58 j 155–168
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transporter expression and activity at the plasma membrane
(recently reviewed in [9]). In addition to NRs as intracellular BA
sensors, some cells also contain BA receptors at the cell surface
including a G-protein coupled receptor (TGR5/M-BAR/GPBAR1)
[10] and the epidermal growth factor receptor (EGFR) [11]. Under
physiological conditions, these regulatory networks preserve the
enterohepatic BA circulation and limit intracellular levels of
potentially toxic BAs. Disturbances of this delicate balance may
contribute to cholestasis, gallstone disease, malabsorption and
intestinal bacterial overgrowth (Fig. 1). By determining the distri-
bution of BAs as signaling molecules with hormonal functions,
transporter alterations also play a key role in fatty liver disease,
insulin resistance, liver regeneration and cancer (Fig. 1). Modiﬁ-
cation of transporters and regulatory NRs may be utilized to
develop novel therapeutic and preventive pharmacological strat-
egies for these diseases. This review provides a comprehensive
summary of the latest advances in understanding the function
of hepatobiliary transporters and their key regulatory NRs for
BA homeostasis in health and diseases, highlighting the potential
clinical and therapeutic implications.
Keypoints
• Hepatic excretion and subsequent enterohepatic 
circulation of bile acids (BAs) require energy demanding 
active transport systems in the liver and intestine that 
are tightly regulated by nuclear receptors (NRs)
• Alterations of hepatobiliary BA transport play a pivotal 
role in the pathogenesis and pathophysiology of 
cholestatic liver injury; regulation of BA transporters by 
NRs may be targeted therapeutically
• Canalicular transporters for cholesterol, BAs and 
phosphatidylcholine and their regulatory NRs determine 
the lithogenicity of bile and the risk of gallstone formation
• BAs play a key role in hepatic lipid and glucose 
homeostasis; disturbances of BA transport with 
subsequent alterations in BA signaling may contribute to 
the pathogenesis and pathophysiology of NAFLD
• BAs are required for liver regeneration, but also 
promote hepatobiliary carcinogenesis; moreover, 
hepatobiliary transporters may be involved in resistance 
to chemotherapy
• Already approved (e.g., UDCA, rifampicin) and novel 
therapeutic agents (e.g., synthetic FXR agonists, 
diseases by modulating BA homeostasis via changes in 
hepatobiliary transporters and their regulatory pathways
norUDCA) exert their beneficial effects in cholestatic liver
Hepatocellular bile acid transporters and their regulation by
nuclear receptors
Basolateral uptake systems in the liver
BAs return to the liver via portal blood (and to amuch lesser extent
via the hepatic artery) and are efﬁciently removedduring their ﬁrst
passage through the hepatic sinusoids by hepatocellular BAuptake
systems [12], involving a sodium-dependent sodium/taurocholate
co-transporting polypeptide (NTCP/SLC10A1) and a family of156 Journal of Hepatology 201sodium-independent multispeciﬁc organic anion transporters
(OATPs/SLCOs) [13,14] (Fig. 2; Table 1).
NTCP accounts for the bulk (about 90%) of BA uptake and was
the ﬁrst clonedBA transporter [13]. Its regulation under physiolog-
ical and pathological conditions is therefore well understood thus
serving as a paradigmaticmodel to understand transporter regula-
tion. NTCP expression is controlled by BAs, hormones such as
estrogen and prolactin, as well as pro-inﬂammatory cytokines
(recently reviewed in [15]). In cholestatic patients [16,17] and ani-
mal models of cholestasis induced by biliary obstruction, estrogen
or endotoxin, NTCP expression is universally reduced (reviewed in
[18]). A key repressivemechanism involves activation of the farne-
soid X receptor (FXR) through accumulating BAs, which then
induces the small heterodimer partner (SHP) as repressor of hepa-
tic nuclear factor 1 alpha and 4 alpha (HNF-1a and HNF-4a, and
also interferingwith retinoid X receptor (RXR), retinoic acid recep-
tor (RAR) heterodimers in rats, or the glucocorticoid receptor in
humans (recently reviewed in [15]), which are all required for nor-
mal NTCP expression (Fig. 2, Table 1).
Canalicular export systems
At the canalicular membrane, highly specialized canalicular trans-
portersmediate excretionof the individual components of bile such
as BAs, phospholipids and cholesterol [4] (Fig. 2, Table 1). The bile
salt export pump (BSEP, ABCB11 or sister of p-glycoprotein (Spgp))
is themajor canalicularBAefﬂux system [19]. The relevance of BSEP
is emphasized by the severe progressive familial cholestatic syn-
drome (PFIC2) or benign recurrent intrahepatic cholestasis (BRIC2)
resulting fromBSEPmutations (Table1). Importantly, the functional
implicationsofBSEPdeﬁciencymaybeunderestimated inknockout
mice (Table 1) where BA composition is less toxic than in humans,
and BAs can be excreted by other canalicular transporters (Table 1).
BSEP expression/activity is tightly controlled at transcriptional and
post-transcriptional levels. FXR [20] upregulates BSEP expression
(recently reviewed in [21]).WhileBSEP isdownregulatedby inﬂam-
matory injury and estrogen, it is relatively well preserved in
obstructive cholestasis, whichmay help limit intracellular BA accu-
mulation, although a preserved bile ﬂowmay cause bile infarcts in
biliary obstruction (recently reviewed in [15]).
The canalicular membrane also contains transport systems
mediating excretion of biliary phospholipids (MDR3, Mdr2 in
rodents, ABCB4) and cholesterol (two half transporters ABCG5/8
which are tightly coupled with BA excretion [22] (Fig. 2, Table 1).
Other canalicular transport systems (Fig. 2, Table 1) are less rel-
evant for BA transport. Multidrug resistance-associated protein
2 (MRP2/ABCC2) mainly excretes bilirubin–glucuronides and glu-
tathione conjugates, but also divalent sulfo-conjugated BAs into
the bile (Fig. 2, Table 1) (Table 1). Multidrug resistance protein
(MDR1, ABCB1) primarily excretes lipophilic cations including
diverse drugs and carcinogens [23], while breast cancer resis-
tance protein (BCRP, ABCG2) facilitates the transport of poten-
tially toxic xenobiotics and food-derived carcinogens [24]
(Table 1). Both transporters have also been implicated in BA
transport when induced under cholestatic conditions, although
this is still disputed in humans.Alternative basolateral efﬂux systems in hepatocytes
During hepatocellular BA overload, BAs can also be transported
back to the sinusoidal blood to protect the liver and for subse-3 vol. 58 j 155–168
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Fig. 1. Overview of diseases linked to disturbances in enterohepatic bile acid circulation. After their synthesis in hepatocytes, bile acids (BAs) are excreted into the bile
and subsequently reabsorbed by enterocytes and, after completing the enterohepatic circulation, by hepatocytes. Efﬁcient reuptake in the ileum preserves 95% of secreted
BAs. Disturbances of transport processes within the enterohepatic circulation cause a variety of hepatic and intestinal disorders. Under normal conditions, BAs ﬁltered by
the kidney are conserved in the kidney (reabsorption in renal tubules) but can be alternatively excreted when BAs accumulate due to impaired biliary excretion in
cholestasis. BAs, bile acids; BRIC, benign recurrent intrahepatic cholestasis; IBD, inﬂammatory bowel disease; ICP, intrahepatic cholestasis of pregnancy; NAFLD, non-
alcoholic fatty liver disease; PBC, primary biliary cholestasis; PFIC; progressive familial intrahepatic cholestasis; PSC, primary sclerosing cholangitis.
JOURNAL OF HEPATOLOGYquent elimination via the urine. Usually this step is coordinated
with phase I and II detoxiﬁcation, providing less toxic and higher
afﬁnity substrates for the basolateral BA export systems [18]. This
alternative basolateral BA export is mediated by the multidrug
resistance-associated proteins MRP3 (ABCC3), MRP4 (ABCC4)
and the heterodimeric organic solute transporter OSTa/OSTb.
Constitutive androstane receptor (CAR; NR1I3), pregnane X
receptor (PXR; NR1I2), vitamin D receptor (VDR, NR1I1) and per-
oxisome proliferator-activated receptor alpha (PPARa, NR1C1) all
increase MRP3 expression in mice, while MRP4 is induced by CAR
and PPARa (recently reviewed in [15]) (Fig. 2, Table 1). The hete-
rodimeric transporters OSTa/OSTb were initially identiﬁed as an
intestinal BA efﬂux system in enterocytes (see below), but are
also found in the liver; their expression is induced via FXR
(reviewed in [25]) (Fig. 2, Table 1).Cholangiocytes and bile acid transport
Bile duct epithelial cells (cholangiocytes) are important modiﬁers
of bile formation by promoting bicarbonate excretion and line the
bile ducts as drainage system for BAs to the intestine. Side chain
modiﬁed BAs such as norUDCAwith a relative resistance to conju-
gation, can bypass the enterohepatic circulation by a process
termed cholehepatic shunting [26]. This process, together withJournal of Hepatology 201potential direct effects of norUDCA on cholangiocyte secretion,
induces bicarbonate-rich hypercholeresis that may represent a
drugable protective mechanism in cholangiopathies [27]. In con-
trast, conjugated BAs require active transport into cholangiocytes
via an apical sodium dependent BA transporter (ASBT), identical
to the transport system in the ileum (see below). After uptake,
BAs are exported into the adjacent peribiliary capillary plexus via
OSTab andMRP3, and possibly a truncated version of ASBT (tABST)
(recently reviewed in [28]). Upregulation of cholangiocellular BA
transport capacity in obstructive cholestasis ([28]), partly by bile
duct proliferation, may facilitate the removal of BAs from the stag-
nant bile. Under physiological conditions, a major role of BA trans-
porters in cholangiocytes could be the regulation of intracellular
concentrations of BAs as signaling molecules. Notably, several
nuclear receptors such as FXR, RXR, LXR, VDR, PPARd, and SHP,
known to play a key role in the regulation of metabolic processes,
are also expressed in cholangiocytes, although their role in bile
duct (patho)biology remains to be clariﬁed.Intestinal bile acid transporters
Apart from a relatively small proportion of passive uptake in the
proximal small intestine and colon, BAs are mainly actively taken3 vol. 58 j 155–168 157
Table 1. Summary of hepatobiliary transporters in hepatocytes, their function, regulation through nuclear receptors and genetic alterations. See supplementary material for all references in this table.
Hepatocellular 
transporters
Main substrates 
[reviewed in 1-5]
Main regulatory 
nuclear receptors
(reviewed in 
[6,7])
Knockout mouse model Human mutations and genetic variants
Bile acid uptake
NTCP
(SLC10A1)
BAs (conjugated/amidated > unconjugated), bromo-
sulfophtalein, dehydroepiandrosterone sulfate, thyroid 
hormones, statins
FXR, RXR, SHP, 
HNF4α, GR
Not available Association with changes in transport capacity for 
taurocholate and statins in Asian population [8, 9]
OATP1A2
(SLCO1A2)
(SLC21A3)
(OATPA)
Conjugated/amidated BAs,estrone-3-sulfate, dehydroepi-
androsterone-3-sulfate, bromosulfophtalein, fexofenadine, 
methotrexate, digoxin, levofloxacin, statins
Minor role
(low hepatic 
expression)
Oatp1a4 (mouse orthologue of OATP1A2) 
knockout mouse: no liver phenotype described in 
naïve mice [10]
Changes in drug disposition [11-13]
OATP1B1
(SLC01B1)
(SLC21A6)
(OATP2)
Conjugated/amidated BAs, bilirubin, bilirubin glucuronide, 
statins, 17β-glucuronosyl estradiol, estrone-3-sulfate, 
repaglinide, angiotensin II receptor antagonists
FXR, SHP, 
HNF4α
Oatp1b2 (mouse orthologue for OATP1B1 and 
OATP1B3) knockout mouse: increased serum 
levels of unconjugated BAs, no change in 
hepatic and biliary BA concentration, reduction 
of cholate clearance [14], moderate conjugated 
hyperbilirubinemia, protected against phalloidin 
induced hepatotoxicity [15], lowered levels of 
hepatic thyroxine resulting in changed glucose 
homeostasis [16]
Association with serum bilirubin levels [17]
Association with presence of bilirubin in the 
gallstones [18]
Influence pharmacokinetics of mycophenolate [19]
OATP1B3
(SLCO1B3)
(SLC21A8)
(OATP8)
Conjugated/amidated BAs, 17β-glucuronosyl estradiol
dehydroepiandrosterone-3-sulfate, cholecystokinin-8
bromosulfophthalein, ouabain, digoxin
FXR, SHP, 
HNF4α
Affect pharmacokinetics of mycophenolate [19]
Canalicular export
BSEP
(ABCB11)
Monovalent conjugated/amidated BAs, taxol FXR, RXR Bsep knockout mouse: mild cholestasis, compen-
sated by formation of less toxic tetrahydroxy BA 
that are exported via alternative canalicular efflux 
systems [20, 21], 50% reduction of bile flow, but 
95% reduction in BA output [22] severe liver injury 
after challenge with CA [23]
PFIC-2 [24, 25]
Increased risk for HCC [26]
BRIC-2 [27]
Association with ICP [28, 29] and contraceptive-
induced cholestasis [30]
Association with improved response to antiviral 
therapy and disease progression in chronic 
hepatitis C [31,32]
Association with drug-induced cholestasis [33]
MRP2
(ABCC2)
Sulfated BAs, tetrahydroxy BAs, glucuronidated bilirubin, 
GSH, leukotriene C4, 17β-glucuronosyl estradiol, estrone 
3-sulfate, cholecystokinin peptide 8, cholyl-L-lysyl-
fluorescein, drugs: methotrexate, doxorubicin, morphine-
3-glucuronide, paclitaxel
FXR, CAR, PXR Spontaneous mutation in GY/TR- and EHBR rat 
[34, 35] lead to hyperbilirubinemia
Mrp2 knockout mouse: increased levels of biliru-
bin and bilirubin glucuronides in serum and urine, 
reduction bile flow, biliary excretion of bilirubin 
glucuronides and total glutathione [36, 37]
Dubin Johnson syndrome [38]
Increased susceptibility for NAFLD [39]
Diclofenac hepatotoxicity [40]
Risk for bile duct cancer [41]
MDR1
(ABCB1)
Polyhydroxylated BAs (in mice only)
Broad substrate specificity for lipophilic cationic com-
pounds (anticancer and immunosuppressive agents, 
antivirals, antibiotic, calcium channel blockers)
PXR Mdr1a and Mdr1b double knockout mouse: de-
creased serum BA levels and increased biliary BA 
output, CA feeding is well tolerated [22], hepatic 
steatosis and obesity [42]
Association with risk for IBD [43] and colorectal 
cancer [44]
BCRP
(ABCG2)
Drugs: methotrexate, imatinib, statins, mitoxantrone, 
topotecan, irinotecan
Porphyrins
BAs?
PXR BCRP knockout mouse: no change in liver injury 
in obstructive cholestasis [45], impaired BA trans-
port in placenta [46]
Susceptibility to drug hepatotoxicity [47, 48]
Influence pharmacokinetics of various drugs [19, 
49, 50]
(continued on next page)
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Table 1 (continued)
ABCG5/8, cholesterol efﬂux pump, ATP-binding cassette, subfamily G, member 5/8; BAs, bile acids; BCRP (ABCG2), breast cancer resistance protein, ATP-binding cassette, subfamily G, member 2; BRIC, benign recurrent
intrahepatic cholestasis; BSEP (ABCB11), bile salt export pump; CA, cholic acid; CAR (NR1I3), constitutive androstane receptor; FXR (NR1H4), farnesoid X receptor/bile acid receptor; GR (NR3C1), glucocorticoid receptor; HCC,
hepatocellular carcinoma; HNF4a (NR2A1), hepatocyte nuclear factor 4 alpha; IBD, inﬂammatory bowel disease, ICP, intrahepatic cholestasis of pregnancy; LXRa (NR1H3), liver X receptor alpha; MDR1 (ABCB1),
p-glycoprotein, multidrug resistance protein 1, ATP-binding cassette, subfamily B, member 1; MDR2/3 (ABCB4), multidrug resistance protein 2/3; MRP2 (ABCC2), multidrug resistanceassociated protein 2, ATP-binding
cassette, subfamily C, member 2; MRP3 (ABCC3) multidrug resistance-associated protein 3, ATP-binding cassette, subfamily C, member 3; MRP4 (ABCC4) multidrug resistance-associated protein 4, ATP-binding cassette,
subfamily C,member 4;NAFLD, non-alcoholic fatty liver disease; NTCP (SLC10A1), sodium/taurocholate cotransporting polypeptide, solute carrier family 10,member 1;OATP1A2 (SLCO1A2,OATP1, OATP-A, SLC21A3), solute
carrier organic anion transporter family, member 1A2; OATP1B1 (SLCO1B1, OATP2, OATP-C, SLC21A6), solute carrier organic anion transporter family, member 1B1; OATP1B3 (SLCO1B3, OATP8, SLC21A8) solute carrier
organic anion transporter family, member 1B3; OSTa/b, organic solute transporter alpha/beta; PBC, primary biliary cirrhosis; PFIC, progressive familial intrahepatic cholestasis; PPARa (NR1C1), peroxisome proliferator-
activated receptor alpha; PSC, primary sclerosing cholangitis; PXR (NR1I2), pregnane X receptor; RXRa (NR2B1), retinoid X receptor alpha; SHP (NR0B2), short heterodimer partner; VDR (NR1I1), vitamin D receptor.
MDR3
(ABCB4)
Phospholipids (phosphatitylcholine) LXR, FXR, 
PPARα
Mdr2 (mouse homolog of MDR3) knockout 
mouse: loss of biliary phospholipid secretion 
[51], cholestatic liver injury with biliary fibrosis 
and sclerosing cholangitis [52, 53], spontaneous 
development of gallstones [54] and HCC [55-57]
PFIC-3 [58, 59]
Association with ICP [60-62]
Heterozygous mutations found in up to one third 
of patients with otherwise unexplained cholestasis 
and portal fibrosis [63]
Modulate the risk of liver disease in cystic fibrosis 
patients [64]
Association with disease progression in Japanese 
PBC patients [65], no strong association in 
European PBC and PSC [66]
Association with gallstone disease [67-69]
ABCG5/
ABCG8
Cholesterol, sitosterol LXR, FXR Single Abcg5 knockout mouse: sitosterolemia, 
reduced plasma cholesterol levels, reduced biliary 
cholesterol and phospholipid concentrations [70]
Single Abcg8 knockout mouse: sitosterolemia, 
impaired biliary cholesterol, but maintained biliary 
sitosterol secretion [71], increased intestinal 
cholesterol and sitostanol absorption and reduced 
but not eliminated hepatic secretion of cholesterol 
[72]
Abcg5/8 double knockout mouse: increased 
absorption of dietary plant sterols, increase in 
plasma sitosterol. Extremely low biliary choles-
terol concentrations, reduced serum und hepatic 
cholesterol levels [73]
Loss of function mutation in ABCG5/8: 
sitosterolemia [74, 75]
Association with gallstone disease [76-80]
Association with LDL cholesterol-lowering 
response to atorvastatin therapy [81]
Association with biliary cancer [82, 83]
Basolateral export
MRP3
(ABCC3)
Divalent BAs (glucuronidated and sulfated)>monovalent 
BAs
glucuronidated bilirubin, glucuronidated-phytoestrogens, 
morphine-3-glucuronide, acetaminophen-glucuronide, 
fexofenadine
CAR, PXR, VDR Mrp3 knockout mouse: no liver phenotype in 
naive mice, low serum bilirubin-glucuronide and 
increased hepatic BA levels in obstructive choles-
tasis [84], attenuated liver injury upon acetami-
nophen treatment due to less GSH depletion [85]
Splice variants with altered hepatic expression 
[86], so far no functional implications
MRP4
(ABCC4)
BAs (sulfated>amidated) in cotransport with GSH, 
urate, cyclic nucleotides, folic acid, conjugated steroids 
(dehydroepiandrosterone 3-sulphate, estradiol-17β-
glucuronate). Drugs: methotrexate, hydrochlorothiazide, 
furosemide, adefovir, tenofovir
CAR, FXR, 
PPARα
Mrp4 knockout mouse: no liver phenotype in 
naive mice, severe liver injury in obstructive cho-
lestasis, but lower serum BA levels [87]
Determine response to nucleoside 
monophosphate analogs, such as 
6-mercaptopurine, in IBD patients [88]
OSTα/OSTβ Conjugated BAs, estrone 3-sulfate, digoxin, prostaglandin 
E2
FXR, LXR OSTα single knockout mouse: small BA pool, 
impaired BA intestinal absorption, less liver injury 
in obstructive cholestasis by improved urinary BA 
clearance [89-91]
Reduced intestinal expression in non-obese 
gallstone patients [92]
Hepatocellular 
transporters
Main substrates 
[reviewed in 1-5]
Main regulatory 
nuclear receptors
(reviewed in 
[6,7])
Knockout mouse model Human mutations and genetic variants
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Fig. 2. Transcriptional regulation of hepatocellular bile formation. Expression of hepatobiliary transporters in hepatocytes determines hepatic bile acid (BA) ﬂux and
hepatocellular concentrations of these potentially toxic metabolites. To ensure the balance between synthesis, uptake and excretion, expression of hepatobiliary
transporters is tightly regulated by nuclear receptors (NRs). NRs provide a network of negative feedback and positive feed-forward mechanisms, for the control of
intracellular concentration of biliary constituents, which are often also ligands for these NRs. BA-activated FXR is a central player in this network, that represses (via
interaction with HNF4 in rats and GR in humans) hepatic BA uptake (NTCP) and (via SHP) synthesis (CYP7A1), promotes bile secretion via induction of canalicular
transporters (BSEP, MRP2, ABCG5/8, MDR3) and induces BA elimination via alternative export systems at the hepatic basolateral (sinusoidal) membrane (OSTa/b). Several
NR pathways converge at the level of CYP7A1 as the rate limiting enzyme in BA synthesis. CAR and PXR facilitate adaptation to increased intracellular BA concentrations by
upregulation of alternative hepatic export routes (MRP3 and MRP4) and induction of detoxiﬁcation enzymes (not shown). Together with RAR, these xenobiotic receptors
also regulate the canalicular expression of MRP2. Cholesterol sensor LXR promotes biliary cholesterol excretion via ABCG5/8. Stimulation of AE2 expression by GR
stimulates biliary bicarbonate secretion thus reducing bile toxicity. Green arrows indicate stimulatory and red lines suppressive effects on target genes. In addition to these
transcriptional mechanisms, post-transcriptional processes (e.g., vesicular targeting of transporters to the membrane, phosphorylation of transport proteins) and
modiﬁcation of the bile through cholangiocytes (e.g., bicarbonate secretion) also play an important role in bile formation (not shown). BAs, bile acids; Bili-glu, bilirubin
glucuronide; BSEP, bile salt export pump; CAR, constitutive androstane receptor; CYP7A1, cholesterol-7a-hydroxylase, FXR, farnesoid X receptor; GR, glucocorticoid
receptor; HNF4, hepatocyte nuclear factor 4, LXR, liver X receptor; MDR3, multidrug resistance protein 3, phospholipid ﬂippase; MRP2, multidrug resistance-associated
protein 2; MRP3, multidrug resistance-associated protein 3; MRP4, multidrug resistance-associated protein 4; NTCP, sodium taurocholate co-transporting polypeptide;
OSTa/b, organic solute transporter alpha and beta, PC, phosphatidylcholine; PXR, pregnane X receptor; PPARa, peroxisome proliferator-activated receptor alpha; RAR,
retinoic acid receptor; SHP, small heterodimer partner.
Reviewup in the terminal ileum via ASBT [29,30]. Notably, enterocytes,
cholangiocytes and renal tubular cells share several BA transport
systems including ASBT [18]. Unlike rats, human and mouse ASBT
is under negative feedback regulation by BAs via FXR and SHP
(reviewed in [25]). After uptake, BAs are bound to the cytosolic
ileal BA binding protein IBABP (also known as ileal lipid binding
protein ILBP and fatty acid binding protein 6, FABP6) and
exported into the portal blood via OSTa/OSTb [25]. The colon is
exposed to BAs escaping ileal reabsorption and possesses
detoxiﬁcation and efﬂux systems (e.g., OSTa/OSTb) for defense
against secondary (unconjugated) BAs formed by the intestinal
ﬂora [18].
After uptake into enterocytes, BAs induce FGF15 in mice (a
homolog of human FGF 19) which acts in an endocrine fashion
to repress the BA synthesis in hepatocytes [31], facilitates gall-
bladder reﬁlling [32] and in a paracrine manner downregulates
ASBT expression [33], altogether leading to reduction of circulat-
ing BAs. Although under physiological conditions FGF19 origi-
nates mainly from enterocytes, patients with obstructive
cholestasis show a profound increase in hepatic FGF19 expres-
sion (not observed in rodents) that correlates with elevated
serum FGF19 levels [34]. In addition, FGF15/19 may also be
actively involved in energy homeostasis since it stimulates hepa-160 Journal of Hepatology 201tic glycogen and protein synthesis, as well as b-oxidation without
inducing lipogenesis [35]. Apart from its signal function in the
portal axis, FGF19 is also secreted into the bile and could have
other signaling functions in exposed cells of the biliary and
enteric tract [36]. Secretion of glucagon-like peptide 1 (GLP-1)
from enteroendocrine cells is mediated by the plasma membrane
BA activated G-protein-coupled receptor TGR5 and represents a
link between BA and glucose metabolism, since GLP-1, secreted
after food intake, facilitates glucose-induced insulin secretion
[37].Role of bile acid transporters in cholestasis –
pathophysiological and therapeutic considerations
Transporter alterations in cholestasis may be primary/pro-chole-
static (e.g., genetic defects (Table 1), inhibition by drugs, repres-
sion by cytokines and oxidative stress), or more often represent
secondary/adaptive changes attempting to minimize liver injury
[18]. In addition to transcriptional and post-transcriptional trans-
porter changes, impaired canalicular contractility and increased
tight junction permeability may also contribute to cholestasis
[38].3 vol. 58 j 155–168
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Pro-inﬂammatory cytokines and oxidative stress impair hepa-
tobiliary transport function at transcriptional and post-transcrip-
tional levels (as recently reviewed in [39,40]). Such mechanisms
are obviously relevant for sepsis/infection-induced cholestasis,
but also play a role in cholestatic hepatitis caused by drugs and
viruses, autoimmune injury, and during obstructive cholestasis
with bacterial overgrowth and translocation. A coordinated hepa-
tic (negative) acute phase response to inﬂammation results in
rapid reduction of bile formation via downregulation of both
basolateral BA uptake (NTCP, OATPs) and canalicular efﬂux sys-
tems (MRP2 and - to a lesser degree – BSEP). Repression of key
regulatory transcriptional networks (HNF1, RXR/RAR, FXR, CAR
and PXR) [15] together with post-transcriptional changes such
as impaired targeting and/or retrieval of efﬂux proteins from
the canalicular membrane [41], all contribute to the reduced
transporter expression. Reduction of the canalicular bilirubin
export pump MRP2 in response to LPS [42] may explain hyperbil-
irubinemia, a well known poor prognostic sign in sepsis. Despite
many clinically relevant cholestatic conditions associated with
inﬂammation, only few studies have addressed this in humans.
As such, basolateral (NTCP, OATP1B1) and canalicular transport-
ers (BSEP and MRP2) are reduced in jaundiced patients with
severe alcoholic hepatitis [43]; MRP2 expression and localization
are also impaired in chronic hepatitis C [44].
Total parenteral nutrition (TPN)-induced cholestasis is accom-
panied by a reduced bile ﬂow in animal models [45], which may
be explained by downregulation of BSEP, MRP2 and Mdr2, follow-
ing repression of regulatory NRs (FXR, CAR and PXR) [46]. In addi-
tion, stigmasterol, a soy-derived lipid, antagonizes FXR activity
[47]. Interestingly, the addition of soybean fat emulsion prevents
hepatic injury by TPN possibly by stimulating PPARa [48]. Nota-
bly, intensive insulin therapy reduces cholestasis and biliary
sludge in critically ill patients [49], which may be linked to regu-
lation of FXR expression by glucose [50].
Certain drugs (e.g., bosentan, rifampicin, glibenclamide, cyclo-
sporine A) induce liver injury with cholestasis. Although drug-
induced (cholestatic) liver injury in most cases is idiosyncratic
(e.g., rifampicin), some of the drugs, such as cyclosporine and
bosentan, can cause cholestasis via dose-dependent inhibition
of BSEP [51]. Other drugs/metabolites such as estradiol 17b-glu-
curonide inhibit BSEP only after secretion into the canalicular
lumen via MRP2 (trans-inhibition) [51], thus constituting a piv-
otal mechanism for oral contraceptive-induced cholestasis.
Patients with BSEP variants may be predisposed to intrahepatic
cholestasis of pregnancy and cholestasis induced by oral contra-
ceptives or hormone replacement (Table 1). Moreover, a frequent
BSEP polymorphism resulting in reduced expression [52], has
been associated with increased risk for cholestatic side effects
by b-lactam antibiotics, psychotropic drugs and proton pump
inhibitors [53] (Table 1).
In chronic forms of cholestatic liver injury (e.g., PBC and PSC)
secondary transporter changes, which may help adapt to accu-
mulating BAs in cholestasis, dominate the picture. These trans-
porter alterations are characterized by downregulation of
uptake systems (NTCP and OATPs) and upregulation of basolat-
eral bile acid export systems (MRP3, MRP4, OSTa/OSTb) [16,54–
56]. In addition, by NR-mediated increases in hydroxylation
(phase I) and conjugation (phase II) enzymes catalyzing a detox-
iﬁcation process producing less toxic, more hydrophilic Bas,
accompany these transporter changes [54]. Such changes may
also explain the biochemical hallmarks of cholestasis, such as ele-Journal of Hepatology 201vations in serum BA levels and conjugated bilirubin, resulting in
jaundice. Notably, these adaptive transporter changes are not
restricted to hepatocytes, but also occur in cholangiocytes,
enterocytes and renal tubular cells [18] to maximize the escape
of BAs under cholestatic conditions.
Animal studies suggest that most of these adaptive alterations
in hepatobiliary transporter systems during cholestasis are med-
iated by regulatory NR pathways controlled by FXR, VDR, CAR,
and PXR, which are activated in response to accumulating BAs
and bilirubin [18,57]. Apparently, these coordinated intrinsic
NR-triggered defense mechanisms are incapable of sufﬁciently
rescuing the liver from chronic cholestatic injury with progres-
sion towards ﬁbrosis and ultimately cirrhosis. Part of these short-
comings may be attributed to impairment of the NR machinery
itself by cholestatic liver injury [54].
Pharmacologic NR agonists can stimulate the defective trans-
porter functions and induce additional detoxiﬁcation pathways
[58]. Ironically, ursodeoxycholic acid (UDCA), the only FDA-
approved drug for the treatment of cholestasis, has poor NR afﬁn-
ity [20,59]. Nevertheless, UDCA has a broad spectrum of actions
including stimulation of the expression of BA detoxifying
enzymes and transporters [60] in addition to beneﬁcial immuno-
modulatory, anti-apoptotic and cytoprotective properties [61].
The effects of UDCA on hepatobiliary transporters appear to be
regulated mainly at post-transcriptional levels such as stimula-
tion of transporter targeting [62], while its transcriptional effects
are limited. As such, UDCA is only a weak ligand for GR [59] and
FXR [20] and indirectly (after enzymatic modiﬁcation to LCA by
intestinal ﬂora) PXR [63]. These effects result in a coordinated
stimulation of canalicular transporter (BSEP and MRP2) and baso-
lateral export pumps (MRP3, MRP4, OSTa/b) as demonstrated in
rodents and patients [60,64,65]. UDCA and dexamethasone, both
synergistically target GR and induce the expression and activity
of the anion (chloride/bicarbonate) exchanger 2 (AE2) in hepato-
cytes and cholangiocytes through coordinated HNF1a/GR/p300
activation [66]. Notably, AE2 is reduced in early PBC [67] with
subsequent impairment of biliary bicarbonate secretion [68,69].
This concept is further corroborated in AE2 knockout mice with
immunologic and some morphologic features of PBC [70]. The
combination of UDCA therapy with budesonide may be superior
to UDCA monotherapy in PBC patients [71] through such syner-
gistic effects on AE2 expression via GR [66].
Novel synthetic BAs are promising alternatives for treatment
of cholestatic disorders. 6-Ethylchenodeoxycholic acid (6-ECDCA,
INT747), is a speciﬁc FXR ligand and highly promising drug can-
didate for cholestatic liver diseases [72]. FXR agonists improve
cholestasis in experimental animals [73], by stimulating hepato-
cellular BA efﬂux via induction of BSEP and basolateral overﬂow
systems (via OSTa/b, while lowering endogenous BA synthesis
and hepatic BA uptake. FXR activation also increases the expres-
sion of MDR3 [74] which may reduce biliary BA toxicity through
increased phospholipid excretion with formation of mixed
micelles. Similarly, PPARa induces MDR3 mRNA expression and
redistributes the localization of the protein to the canalicular
membrane [75] which could contribute to the beneﬁcial effects
of ﬁbrates in PBC patients with a suboptimal response to UDCA
[76,77]. However, it should be considered that MDR3 is already
highly expressed in PBC patients [16] and may not be further
increased by bezaﬁbrate [78]. In recent phase II clinical trials in
patients with PBC, 6-ECDCA alone or in combination with UDCA
had beneﬁcial effects on cholestasis, despite development of3 vol. 58 j 155–168 161
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pruritus at higher doses [72]. Targeting FXR with a dual FXR/
TGR5 agonist, INT767, in the Mdr2 (human MDR3) knockout
mouse cholangiopathy model, uncovered FXR-induced bicarbon-
ate secretion as a key therapeutic mechanism [79].
A side chain shortened modiﬁcation of UDCA, norUDCA, with
relative resistance to amidation, represents a promising treat-
ment for cholangiopathies as revealed in the Mdr2 (human
MDR3) knockout mouse model resembling PSC [80]. norUDCA
is anticholestatic, antiﬁbrotic and anti-inﬂammatory and under-
goes cholehepatic shunting, also inducing a bicarbonate-rich
and potentially less toxic bile ﬂow [27,81]. Moreover, norUDCA
improves cholestatic liver injury via marked upregulation of
phase I and phase II detoxiﬁcation enzymes and the alternative
basolateral efﬂux system, and subsequent increase in renal BA
excretion [27,80] and restores deranged hepatic lipid metabolism
in these mice [82]. So far, no NR targeted by norUDCA has been
identiﬁed.
PXR (e.g., rifampicin) and CAR (e.g., phenobarbital and Yin
Chin, a traditional Chinese herb) ligands have been used to treat
pruritus and/or jaundice, long before their exact molecular mode
of action was identiﬁed [77,83,84]. Activation of PXR and CAR
induces the BA and bilirubin detoxiﬁcation machinery via phase
I and II enzymes and subsequent elimination via alternative
hepatocellular efﬂux pumps in animals models of cholestasis
[85] and humans [60].
Collectively, changes in BA transporters constitute a central
element in the pathogenesis and clinical manifestation of chole-
stasis and several clinically effective drugs modulate transporter
expression via regulatory NRs, translating into a reduction of the
hepatocellular BA burden thus ameliorating cholestasis.Gallstone disease
High cholesterol or low BA and phospholipid concentrations, as
well as BA and phospholipid species, determine the lithogenicity
of bile [86]. Therefore, canalicular transporters for cholesterol
(ABCG5/8), BAs (BSEP) and phosphatidylcholine (MDR3/Mdr2 in
rodents) and their regulatory NRs are relevant for gallstone for-
mation. Quantitative trait locus analysis in gallstone susceptible
mice deﬁned ABCG5/G8 as candidate genes for gallstone suscepti-
bility [87] and its variants were linked to gallstone disease in Chi-
nese, German, Chilean, Indian and Swedish populations (recently
reviewed in [88]). Moreover, the expression of ABCG5/8 and its
regulatory NR liver X receptor (LXR) (Fig. 2) was increased and
correlated with cholesterol saturation in Chinese non-obese gall-
stone patients [89]. The role of LXR in gallstone formation is fur-
ther emphasized by transgenic mice which are susceptible to
cholesterol gallstone formation [90]. A possible explanation for
the link between the metabolic syndrome and gallstones comes
from mice lacking the hepatocellular insulin receptor. Increased
gallstone formation in these mice has been attributed to
increased biliary cholesterol excretion resulting from upregula-
tion of ABCG5/8 due to induction of the forkhead transcription
factor FoxO1 and downregulation of BA synthesis [91].
BRIC 2 patients with mutations of BSEP are predisposed to
gallstones (Table 1), while its hepatic overexpression in mice
increases the risk of cholesterol gallstone [92]. The role of
MDR3 is underlined by spontaneous gallstone formation in mice
lacking Mdr2 (MDR3 in humans) [93] and ‘‘low phospholipid-
associated cholelithiasis’’ in humans with MDR3 mutations [94].162 Journal of Hepatology 201However, a large population study did not reveal signiﬁcant asso-
ciations between BSEP or MDR3 variants and gallstone disease
[95]. FXR (a known inducer of BSEP and MDR3) is litho-protective
and mice lacking FXR are prone to form gallstones [96]. Con-
versely, pharmacological activation of FXR counteracts gallstone
formation [96]. A distinct FXR genetic variant was associated with
gallstone disease in male Mexicans, whereas no such links were
found in Chilean and German populations [97], emphasizing
the complexity of multiple genetic factors determining the gall-
stone disease.
Intestinal BA transporters may also be involved in determin-
ing the BA pool size as key factor of cholesterol homeostasis. As
such, downregulation of ASBT [98], as wells as OSTa/b (Table 1),
was found in gallstone patients. In addition, ASBT polymorphisms
represent a risk factor for gallstone disease [99].Pathophysiologic and therapeutic signiﬁcance of intestinal
bile acid transport and signaling
Inﬂammatory cytokines downregulate ASBT via the activator pro-
tein 1. This may explain BA malabsorption in patients with ileal
inﬂammation and animal models of ileitis, as well as downregu-
lation of ASBT in patients with Crohn’s disease [100]. Whether
this contributes to diarrhea and possibly also BA-induced carci-
nogenesis in the colon, remains to be identiﬁed. Notably, ASBT
polymorphisms have been associated with an increased risk of
colorectal adenoma [101], although no association with colorec-
tal carcinoma was found [102]. Under normal conditions, BA-acti-
vated FXR controls bacterial overgrowth and maintains the
epithelial barrier integrity by induction of multiple anti-inﬂam-
matory genes [103] and pharmacological activation of FXR has
beneﬁcial effects in the mouse model of colitis [104]. Moreover,
intestinal overexpression of FXR protects the intestine from cho-
lestasis-associated mucosal injury and reduces cholestatic liver
injury, the latter by repression of bile acid synthesis via the
FXR-FGF15/19-FGRR4-CYP7A1 axis [105].
The interruption of the enterohepatic circulation by BA
sequestrants may be used therapeutically to eliminate BAs or
other pruritogens in the treatment of cholestatic pruritus. Nota-
bly, serum BA levels correlate only poorly with the degree of
cholestatic pruritus and a recently identiﬁed product of the lyso-
phospholipase autotaxin, lysophosphatidic acid, may be a major
mediator of pruritus [106]. Furthermore, BA sequestrants are
used to treat BA-induced diarrhea and metabolic disorders such
as hyperlipidemia and diabetes. They have been shown to
improve the glycemic control in diabetic patients [107], by mech-
anisms involving secretion of GLP-1 [108]. Long before BA
sequestrants were used in the treatment of diabetes, their bene-
ﬁcial effects in hypercholesterolemia and atherosclerosis became
apparent [109]. Similarly, ileal bypass surgery also reduced over-
all mortality from coronary heart disease [110]. The results of
these studies can now be explained by decreased FGF19 signal-
ing, and derepression of CYP7A1 increasing the conversion of
cholesterol to BAs. Hepatic depletion of cholesterol then
increases the sterol regulatory element-binding protein 2, which
in turn induces the LDL receptor and lowers the LDL cholesterol.
In analogy to BA sequestrants, ASBT inhibitors are attractive can-
didate compounds to treat hypercholesterolemia and atheroscle-
rosis [111,112], but their use may be limited by diarrhea.
Nevertheless, this ‘side effect’ may be used to treat constipation3 vol. 58 j 155–168
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[113], since BAs promote colonic ﬂuid and electrolyte secretion
[26,114] and some forms of idiopathic constipation have recently
been linked to impaired colonic BA metabolism/signaling
[115,116]. Conversely, up to one third of patients with chronic
diarrhea may suffer from BA malabsorption [117], which may
be successfully treated with BA binding resins [118].Bile acid transporters and fatty liver disease
During the last decades, it has become apparent that BAs are not
only detergents, but also possess a number of hormonal effects
on lipid and glucose metabolism/storage (recently reviewed in
[119]). BAs, via FXR and its downstream targets including SHP,
control hepatic de novo lipogenesis, very low density lipopro-
tein-triglycerides export and plasma triglyceride turnover. BA-
activated FXR is also involved in the regulation of hepatic gluco-
neogenesis, glycogen synthesis and insulin sensitivity. Postpran-
dially, when serum BA concentration increase, BAs escape from
the enterohepatic circulation by spillover and thereby reach tis-
sues such as adipose tissue and skeletal muscle, usually not
exposed to signiﬁcant BA levels during fasting. via TGR5, BAs
are able to stimulate GLP-1 secretion in the small intestine, and
energy expenditure in brown adipose tissue and skeletal muscle
[120].
Since hepatobiliary transporters critically determine hepatic
BA ﬂux and concentrations, it is attractive to hypothesize that
alterations of BSEP – the rate limiting step for BA efﬂux – could
contribute to the pathogenesis of non-alcoholic fatty liver disease
(NAFLD). Indeed, mice overexpressing BSEP have increased bili-
ary lipid secretion and are protected from steatosis when fed
an atherogenic diet [121]. In line with this, BSEP over-expression
lowered hepatic lipid accumulation, but not inﬂammation in
mice fed with a methionine–choline deﬁcient diet, as model for
steatohepatitis [122]. Mice lacking FXRwith low BSEP expression,
spontaneously develop hepatic steatosis and hypertriglyceride-
mia associated with insulin resistance, emphasizing the role of
BA signaling in lipid and glucose metabolism (recently reviewed
in [73,120]). Recent studies have reported a positive association
between BSEP variants and increased serum triglycerides and
cholesterol levels [123] and obesity [124] in humans. In contrast
to the association between common BSEP polymorphisms and
cirrhosis in hepatitis C, no such association was found for
advanced ﬁbrosis in NAFLD patients (Table 1). However, unlike
MRP2, BSEP protein levels were not reduced in animal models
of NAFLD, although mRNA levels were also lower [125]. The role
of BSEP in lipid metabolism was emphasized by a recent study
revealing that cellular energy depletion activates AMPK–SRC-2
pathway which, via BSEP activation, promotes the intestinal
absorption of dietary fat [126]. Therefore, pharmacologic thera-
pies targeting BSEP and/or FXR may be beneﬁcial in the manage-
ment of NAFLD.
As another canalicular transporter, MRP2 may be involved in
the pathogenesis of NAFLD. Downregulation of MRP2 in obese
Zucker rats with defective leptin signaling [125] may lead to
accumulation of potentially toxic metabolites. Furthermore,
MRP2 polymorphisms have been linked to NAFLD susceptibility
and progression (Table 1). Interestingly, MRP2 expression was
increased in ob/ob mice as another model of NAFLD and leptin
deﬁciency [127].
Currently, no approved drugs for the treatment of NAFLD
exist. UDCA is capable of modulating transporter expressionJournal of Hepatology 201[60,64,128], but clinical trials (including high dose studies) of
NAFLD and NASH are rather disappointing [129]. In contrast to
humans, taurine-conjugated UDCA reduces endoplasmic reticu-
lum stress in mice thereby reversing insulin resistance [130]
although this mechanism is still controversial [131]. Notably,
high dose UDCA improves biochemical markers of liver injury,
ﬁbrosis and insulin resistance in patients with NASH [132].
The key role of FXR and TGR5 in regulation of lipid and glu-
cose metabolism places these BA receptors in the center of inter-
est for future management of NAFLD. In fact, several studies in
animal models for obesity and NAFLD have recently demon-
strated the beneﬁcial effects of pharmacological stimulation of
FXR and TGR5 on hepatic steatosis and insulin resistance. As
such, the FXR agonist INT747 improves insulin sensitivity and
liver function in humans [133], whereas another FXR agonist
(WAY-362450) attenuates liver inﬂammation and ﬁbrosis in a
mouse model of fatty liver [134]. INT777, a TGR5 activator,
reduces hepatic steatosis in mice, induced by high fat feeding,
by promoting energy expenditure and GLP-1 secretion [37].
Taken together, a dual agonist activating both FXR and TGR5,
such as the INT767, may be promising for NAFLD treatment.
GLP-1 receptor is also expressed in human hepatocytes [135]
and reduced in NASH [136]. Moreover, GLP-1 treatment reduces
steatosis in mice [137]. BA sequestrant-mediated activation of
GLP-1 in the intestine (see above) could therefore also promote
GLP-1 receptor activity in the liver that in turn increases PPARa
and PPARc as well as AMPK expression and stimulates b-oxida-
tion, lipid storage and reactive oxygen species detoxiﬁcation
[136,137].Liver regeneration and cancer
Bile formation is impaired after partial hepatectomy (PH) [138]
which results in cholestasis with elevated serum BA levels. Baso-
lateral NTCP, OATP1 and OATP2 are downregulated [139,140],
while the canalicular transporters MRP2 and BSEP are maintained
or even increased after up to 70% PH [140,141]. However, loss of
functional liver tissue by massive PH (up to 90%) is associated
with diminished MRP2 expression and consecutive hyperbilirubi-
nemia [142], which may contribute to postoperative jaundice.
The molecular mechanisms involve cytokines such as IL6 and
TNFa, key repressors of the basolateral transporter expression
via HNF1a; conversely TNFa inactivation restores the transporter
expression [143]. Intracellular BA overload after loss of functional
liver mass can be counteracted by upregulation of the alternative
basolateral BA export pumps MRP3 [142] and MRP4 [139]. The
importance of these adaptive changes for liver regeneration is
underlined by delayed liver regeneration in mice lacking MRP3
with subsequently lowered BA concentration in the portal blood,
and impaired FXR signaling [144].
Importantly, increased BA levels during liver injury may also
have mechanistic relevance for liver repair. Interruption of the
enterohepatic circulation delays liver regeneration [145] and
BAs are able to stimulate hepatocyte proliferation [146], effects
recently attributed to FXR and its downstream cell cycle regulator
forkhead box m1b [147]. As such, elevated BAs accelerate liver
growth and promote liver regeneration, which is in turn impaired
in mice lacking FXR [148]. In addition to the protective role of
hepatic FXR, intestinal FXR activation of FGF15 pathway protects
the hepatocytes from cell death by repressing BA synthesis after
PH [149,150]. In pregnancy, a condition known to be3 vol. 58 j 155–168 163
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accompanied by gestational hepatomegaly, loss of FXR leads to
impairment of liver growth [151].
Besides their role in promoting liver repair, BA exposure
together with inﬂammatory stimuli may play a role in carcino-
genesis. Mice lacking FXR or Mdr2 with impaired BA homeostasis
and inﬂammation spontaneously develop hepatocellular carci-
noma (HCC) [152,153] and treatment with cholestyramine
reduces tumor frequency [153]. Similar to human HCC, activation
of the Wnt-b-catenin pathway is an early event even before
tumor formation in FXR knockout mice [154]. Reduced FXR
expression and activity have also been reported in human HCC
[154] and in colon cancer [155]. Moreover, children with progres-
sive familial intrahepatic cholestasis due to deﬁciency of the FXR
target BSEP have an increased risk of HCC (Table 1) and cases of
cholangiocarcinoma are described in patients with BSEP deﬁ-
ciency [156]. Reduced FXR expression has been recently shown
in cholangiocellular carcinoma, while TGR5 has profoundly
increased [157]. Preliminary data suggest that TGR5 may mediate
resistance of cancer cells to apoptosis [157].
Treatment of HCC is limited by resistance to chemotherapy,
which might be mediated by MDRs and MRPs and reduced hepa-
tocellular drug uptake into HCCs, because of their capacity to
export the anticancer drug out of expressing cells. The expression
pattern of these transporters varies between individual patients
[158]. Moreover, the expression of hepatobiliary (BA and organic
anion) transporters is not only interesting for the therapeutic
outcome, but also represents a determinant for radiological
detection of HCC, since hepatocyte-selective enhancement with
contrast agent on magnetic resonance images correlates with
the expression pattern of OATPs and MRP2 [159]. Collectively,
these ﬁndings underpin the diagnostic and therapeutic relevance
of BA transporters for liver cancer.Summary and future directions
Hepatobiliary transporters are crucial to preserve bile formation
and enterohepatic circulation of BAs. Within the enterohepatic
circulation, BAs exert numerous functions such as facilitating
intestinal lipid absorption, clearance of potentially toxic mole-
cules and regulation of lipid, glucose and energy homeostasis.
Disturbances in these delicate processes may result in a variety
of hepatic, intestinal and systemic disorders. In addition, hepatic
and intestinal diseases may induce secondary changes in trans-
porter expression and regulation, thus affecting BA homeostasis.
Understanding the mechanisms of BA transport and its regulation
under (patho)physiologic conditions represents a powerful tool
for the development of novel therapeutic approaches to many
hepatic diseases with misbalanced BA metabolism. Targeting
hepatobiliary transporters and their regulatory NRs should there-
fore open new therapeutic avenues for a broad range of diseases
of the liver and beyond.Conﬂict of interest
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